X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA DR. REDDYS LAB SHASUN PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 123.9 29.1 425.3% View Chart
P/BV x 8.5 3.6 237.6% View Chart
Dividend Yield % 0.2 0.7 31.8%  

Financials

 SHASUN PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
DR. REDDYS LAB
Mar-18
SHASUN PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs942,788 3.4%   
Low Rs461,902 2.4%   
Sales per share (Unadj.) Rs214.2860.8 24.9%  
Earnings per share (Unadj.) Rs5.357.1 9.4%  
Cash flow per share (Unadj.) Rs15.8122.0 13.0%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %1.40.9 167.7%  
Book value per share (Unadj.) Rs53.3757.7 7.0%  
Shares outstanding (eoy) m56.62165.91 34.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x0.32.7 12.0%   
Avg P/E ratio x13.141.1 31.9%  
P/CF ratio (eoy) x4.419.2 23.0%  
Price / Book Value ratio x1.33.1 42.3%  
Dividend payout %18.735.0 53.5%   
Avg Mkt Cap Rs m3,958389,034 1.0%   
No. of employees `000NA23.5 0.0%   
Total wages/salary Rs m2,16432,149 6.7%   
Avg. sales/employee Rs ThNM6,070.8-  
Avg. wages/employee Rs ThNM1,366.6-  
Avg. net profit/employee Rs ThNM402.5-  
INCOME DATA
Net Sales Rs m12,127142,810 8.5%  
Other income Rs m2291,552 14.8%   
Total revenues Rs m12,356144,362 8.6%   
Gross profit Rs m1,00923,512 4.3%  
Depreciation Rs m59410,772 5.5%   
Interest Rs m415788 52.7%   
Profit before tax Rs m23013,504 1.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0344 -0.1%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-734,380 -1.7%   
Profit after tax Rs m3029,468 3.2%  
Gross profit margin %8.316.5 50.5%  
Effective tax rate %-31.732.4 -97.6%   
Net profit margin %2.56.6 37.6%  
BALANCE SHEET DATA
Current assets Rs m6,884104,984 6.6%   
Current liabilities Rs m8,45668,938 12.3%   
Net working cap to sales %-13.025.2 -51.3%  
Current ratio x0.81.5 53.5%  
Inventory Days Days6274 82.9%  
Debtors Days Days108104 103.8%  
Net fixed assets Rs m4,970104,385 4.8%   
Share capital Rs m113830 13.7%   
"Free" reserves Rs m2,875124,886 2.3%   
Net worth Rs m3,020125,716 2.4%   
Long term debt Rs m1,81725,089 7.2%   
Total assets Rs m13,347225,443 5.9%  
Interest coverage x1.618.1 8.6%   
Debt to equity ratio x0.60.2 301.5%  
Sales to assets ratio x0.90.6 143.4%   
Return on assets %5.44.5 118.1%  
Return on equity %10.07.5 132.8%  
Return on capital %13.39.7 137.3%  
Exports to sales %46.40-   
Imports to sales %14.20-   
Exports (fob) Rs m5,622NA-   
Imports (cif) Rs m1,728NA-   
Fx inflow Rs m5,84372,623 8.0%   
Fx outflow Rs m2,17318,916 11.5%   
Net fx Rs m3,66953,707 6.8%   
CASH FLOW
From Operations Rs m39818,030 2.2%  
From Investments Rs m-1,635-14,883 11.0%  
From Financial Activity Rs m1,309-4,440 -29.5%  
Net Cashflow Rs m71-1,236 -5.8%  

Share Holding

Indian Promoters % 39.2 25.5 153.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 5.4 66.7%  
FIIs % 17.6 35.3 49.9%  
ADR/GDR % 0.0 18.5 -  
Free float % 39.6 15.3 258.8%  
Shareholders   20,750 75,885 27.3%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   NATCO PHARMA  PANACEA BIOTECH  CADILA HEALTHCARE  ABBOTT INDIA  PLETHICO PHARMA  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Recover; Healthcare & IT Stocks Witness Buying(12:30 pm)

Share markets in India have trimmed their early losses and are presently trading marginally lower. Sectoral indices are trading mixed with stocks.

Related Views on News

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS